Geopolitical instability impacting global business
Management highlighted geopolitical risks as a key concern given the company's international presence, though diversification mitigates impact.
ALIVUS / Q3-FY26 / risks
Keep the risk register visible.
Alivus Life Sciences · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
CDMO growth slower than peers due to smaller deal sizes
Analyst questioned why CDMO deal sizes are limited to $4-6M vs peers targeting $50-100M; management defended strategy citing high attrition and tax-driven manufacturing in Ireland.
Pricing erosion in mature molecules
Management acknowledged 4-4.5% annual price erosion across the portfolio, but expects to offset via next-gen processes and new launches.
Sholapur capacity delay and scale-down
Sholapur plant delayed by ~3 months to July 2026, and initial capacity reduced from 600kL to 450-500kL, though management says it won't impact growth.